Why does valproic acid deplete carnitine when other seizure medications do not?

Valproic acid uniquely inhibits carnitine biosynthesis enzymes and enters mitochondria as a fatty acid analog that directly consumes carnitine during beta-oxidation. The resulting valproylcarnitine is excreted irreversibly in urine, creating a net carnitine drain. CTD documents 34,261 gene interactions for valproate — including carnitine transporter gene SLC22A5 — that other anticonvulsants do not target. L-carnitine supplementation (1-3g daily) is standard of care.

Should I take L-carnitine supplements with valproic acid?

Yes. L-carnitine supplementation (1-3g daily in divided doses) prevents hyperammonemia and reduces hepatotoxicity risk from valproate-induced carnitine depletion. Many neurologists routinely prescribe L-carnitine alongside valproate, especially for children, patients on polytherapy, and anyone with baseline metabolic concerns. Monitor free carnitine levels (target above 30 µmol/L) and ammonia (target below 35 µmol/L) every 3-6 months.

Is folate supplementation critical for women on valproic acid?

Absolutely. Valproate is the most teratogenic common medication, causing neural tube defects in 1-2% of exposed pregnancies — a rate 10-20 times higher than baseline. Folate supplementation (1-5 mg daily of L-methylfolate) is essential for all women of childbearing age on valproate. Ideally, women planning pregnancy should transition to a less teratogenic anticonvulsant under neurologist guidance. PharmGKB annotations link MTHFR variants to variable folate metabolism affecting supplementation needs.

Can valproic acid cause hair loss through nutrient depletion?

Yes. Valproate causes hair loss through at least two nutrient pathways: biotin depletion affects keratin structure in hair follicles, while carnitine depletion impairs cellular energy production needed for hair growth. FAERS adverse event data documents hair loss among the most commonly reported valproate side effects. Biotin supplementation (5-10 mg daily) combined with L-carnitine often reduces hair shedding within 2-3 months.

Why do I need to monitor ammonia levels on valproic acid?

Valproate-induced carnitine depletion disrupts mitochondrial fatty acid oxidation, causing ammonia to accumulate as a metabolic byproduct. Ammonia above 35 µmol/L can cause encephalopathy — confusion, lethargy, and behavioral changes that mimic seizure activity or psychiatric decompensation. Regular ammonia monitoring catches this complication early, allowing carnitine supplementation to restore fatty acid metabolism before neurological damage occurs.

Does valproic acid weaken bones?

Yes. Valproate depletes three bone-critical nutrients simultaneously: vitamin D through CYP24A1 enzyme induction, calcium through secondary absorption impairment, and vitamin K through metabolic pathway interference. This triple depletion creates compounding bone mineral loss over years of treatment. Children and postmenopausal women face the greatest skeletal risk. DEXA scanning every 1-2 years is recommended for long-term valproate users, alongside vitamin D (2,000-5,000 IU daily) and calcium supplementation.

6 Nutrients Affected · Based on CTD Molecular Database

What Does Valproic Acid Deplete? 6 Nutrients Affected

Valproic acid (Depakote, Depakene, Stavzor) depletes carnitine, folate, vitamin D, calcium, vitamin K, and biotin through HDAC inhibition, enzyme induction, and impaired biosynthesis. Prescribed approximately 15 million times annually, valproic acid has the largest molecular footprint of any medication in the Comparative Toxicogenomics Database: 34,261 gene interactions across 29,821 disease associations with 387 curated entries. Carnitine depletion is unique to valproate — no other common medication causes it — and can trigger fatal hepatotoxicity in children if left unmonitored.

Taking this medication? Check what it depletesFree, 10 seconds →

Data sourced from CTD, ChEMBL, FAERS, PubMed, PharmGKB. How we verify this data →

Sources verified as of April 2026

[01]

Depletions Overview

Carnitine

High

Valproic acid inhibits carnitine biosynthesis enzymes and dramatically increases renal carnitine excretion, creating a dual depletion pathway unique to this medication. Valproate is metabolized through beta-oxidation as a fatty acid analog, directly consuming carnitine as a cofactor and producing valproylcarnitine that is excreted in urine. According to CTD data documenting 34,261 gene interactions, valproate affects carnitine transporter genes (SLC22A5) and carnitine palmitoyltransferase genes that no other common anticonvulsant targets.

Onset: Weeks to months

Folate

High

Valproic acid increases folate metabolism through enzyme induction while simultaneously interfering with folate absorption in the small intestine. As an HDAC inhibitor affecting gene expression across the genome, valproate alters methylation dynamics that depend on folate-derived methyl groups. This depletion is critically dangerous for women of childbearing age because valproate is the most teratogenic common medication, causing neural tube defects in 1-2% of exposed pregnancies — a rate 10-20 times higher than the general population.

Onset: Weeks to months

Persistent fatigue that deepens over months of treatmentBrain fog and cognitive slowing that mimics undertreated epilepsyMood instability and irritability between seizure episodesMacrocytic anemia with elevated MCV on blood workElevated homocysteine increasing cardiovascular risk

Vitamin D

Moderate

Valproic acid induces CYP24A1, the enzyme that catabolizes active vitamin D metabolites into inactive calcitroic acid. This accelerated breakdown reduces circulating 25-hydroxyvitamin D levels over months of treatment. The HDAC inhibition mechanism also affects vitamin D receptor gene expression, compounding the catabolic effect with reduced receptor sensitivity. Many epilepsy patients already have reduced sun exposure due to activity restrictions, amplifying the medication-induced deficit.

Onset: Months

Deep bone pain especially in the shins, hips, and lower backMuscle weakness distinct from carnitine-related weaknessIncreased susceptibility to fractures from minor impactsGradual development of osteopenia visible on DEXA scansLow mood and seasonal depression patterns

Calcium

Moderate

Calcium depletion occurs secondary to vitamin D deficiency because active vitamin D is required for intestinal calcium absorption. When valproate-induced CYP24A1 induction accelerates vitamin D breakdown, the downstream calcium absorption pathway is impaired. Long-term valproate users face compounded bone mineral loss through simultaneous vitamin D and calcium deficiency, with the risk most severe in children and adolescents whose bones are still developing and in postmenopausal women.

Onset: Months

Muscle cramps and spasms especially in the calves at nightGradual bone thinning visible on repeat DEXA scanningDental problems including weakening enamel and increased cavitiesTingling or numbness in the fingers and around the mouthIncreased fracture risk from falls that would not normally cause breaks

Vitamin K

Low

Valproic acid interferes with vitamin K metabolism through enzyme pathway alterations that reduce the recycling of vitamin K epoxide back to its active form. This disruption affects the vitamin K-dependent carboxylation of clotting factors II, VII, IX, and X, as well as bone proteins like osteocalcin. The effect is mild in most adults but becomes clinically significant in neonates born to mothers on valproate, who may present with vitamin K deficiency bleeding.

Onset: Months

Bruising more easily than before starting the medicationBleeding gums when brushing teethMinor cuts that take noticeably longer to stop bleedingNosebleeds that occur more frequentlyBone fragility compounding the calcium and vitamin D effects

Biotin

Low-Moderate

Valproic acid increases biotin catabolism by accelerating the activity of biotinidase and altering biotin-dependent carboxylase enzymes. As an HDAC inhibitor, valproate changes the acetylation state of histones that regulate biotin-responsive genes. Biotin deficiency from valproate develops slowly over months and is often the last depletion recognized because its symptoms — hair loss, skin rash, brittle nails — are frequently attributed to other causes.

Onset: Months

Hair thinning and increased shedding especially from the scalpDry scaly skin rash around the eyes, nose, and mouthBrittle nails that crack and split more than usualTingling and numbness in the hands and feetFatigue that compounds the carnitine-related energy deficit

Wondering about YOUR specific medications?

Check free — no signup, 10 seconds →

[02]

How It Causes Depletions

Valproic acid is prescribed approximately 15 million times annually in the United States under brand names Depakote, Depakene, and Stavzor for epilepsy, bipolar disorder, and migraine prevention. According to ChEMBL mechanism-of-action data, valproate functions through at least three distinct pharmacological mechanisms: succinate semialdehyde dehydrogenase inhibition, histone deacetylase (HDAC) inhibition affecting HDAC1, HDAC2, and HDAC8, and GABA transaminase inhibition that increases inhibitory neurotransmitter levels. The HDAC inhibitor activity is what makes valproate unique among anticonvulsants — it directly modifies gene expression across the entire genome by altering histone acetylation, explaining its extraordinarily large molecular footprint. Valproate has 90% oral bioavailability, reaches peak plasma concentration at 4 hours, carries only 10% protein binding (uniquely low among anticonvulsants), and has a 16-hour elimination half-life. The low protein binding means 90% of circulating valproate is pharmacologically active, contributing to its broad metabolic effects.

The Comparative Toxicogenomics Database documents 34,261 gene interactions for valproic acid — the largest molecular footprint of any medication in the entire database, exceeding even dexamethasone's 11,540 gene interactions by threefold. This extraordinary reach stems from the HDAC inhibitor mechanism: by changing histone acetylation patterns, valproate alters the transcription of thousands of genes simultaneously, including genes governing carnitine transport (SLC22A5), folate metabolism (MTHFR, DHFR), vitamin D catabolism (CYP24A1), and biotin-dependent carboxylases. FAERS adverse event data captures 30,120 total reports for valproic acid, with hepatotoxicity, hyperammonemia, and teratogenicity among the most serious documented outcomes. The carnitine depletion pathway is particularly well characterized in PubMed: valproate enters mitochondria as a fatty acid analog, consumes carnitine during beta-oxidation, and produces valproylcarnitine that is irreversibly excreted in urine, creating a net carnitine drain that no dietary intake alone can replenish.

Across 3,337 PubMed-indexed articles and 43 randomized controlled trials involving 75,066 patients, valproic acid's nutrient depletion profile is the most complex of any commonly prescribed medication. The folate depletion carries the most severe clinical consequence: valproate is the most teratogenic common medication, causing neural tube defects in 1-2% of exposed pregnancies. PharmGKB pharmacogenomic annotations link valproate response to genetic variants in UGT1A6 and CYP2C9 that affect drug metabolism, as well as POLG mitochondrial DNA polymerase mutations that dramatically increase hepatotoxicity risk when combined with carnitine depletion. The six simultaneous nutrient depletions create compound deficiency syndromes: carnitine depletion impairs energy production, folate depletion disrupts methylation and cell division, vitamin D and calcium depletion weaken bones, vitamin K depletion impairs clotting, and biotin depletion affects skin, hair, and neurological function. Comprehensive supplementation and monitoring are not optional for valproate users — they are essential for safe long-term treatment.

[03]

Symptoms to Watch For

Severe muscle weakness that worsens over weeks of treatmentProfound fatigue and low energy not improving with restElevated ammonia causing confusion or altered mental statusNausea and vomiting from liver stressUnexplained weight gain from impaired fatty acid metabolismPersistent fatigue that deepens over months of treatmentBrain fog and cognitive slowing that mimics undertreated epilepsyMood instability and irritability between seizure episodesMacrocytic anemia with elevated MCV on blood workElevated homocysteine increasing cardiovascular riskDeep bone pain especially in the shins, hips, and lower backMuscle weakness distinct from carnitine-related weaknessIncreased susceptibility to fractures from minor impactsGradual development of osteopenia visible on DEXA scansLow mood and seasonal depression patternsMuscle cramps and spasms especially in the calves at nightGradual bone thinning visible on repeat DEXA scanningDental problems including weakening enamel and increased cavitiesTingling or numbness in the fingers and around the mouthIncreased fracture risk from falls that would not normally cause breaksBruising more easily than before starting the medicationBleeding gums when brushing teethMinor cuts that take noticeably longer to stop bleedingNosebleeds that occur more frequentlyBone fragility compounding the calcium and vitamin D effectsHair thinning and increased shedding especially from the scalpDry scaly skin rash around the eyes, nose, and mouthBrittle nails that crack and split more than usualTingling and numbness in the hands and feetFatigue that compounds the carnitine-related energy deficit

Valproic acid depletes 6 nutrients simultaneously across different timelines, creating a complex symptom picture that evolves over months of treatment. Carnitine and folate depletions are the most clinically dangerous — carnitine deficiency can cause fatal hepatotoxicity in children, while folate deficiency during pregnancy causes neural tube defects. The remaining depletions (vitamin D, calcium, vitamin K, biotin) develop more gradually but compound into significant bone, immune, and integumentary effects that worsen with prolonged use.

[04]

What to Monitor

Request these at your next appointment. Check the ones you want to remember.

Free Carnitine (>30 µmol/L)

Standard metabolic panels do not include carnitine. Valproate is the only common medication that causes carnitine depletion, making this test essential and specific to valproate users. Free carnitine below 20 µmol/L significantly increases hepatotoxicity risk. L-carnitine supplementation (1-3g daily) is considered standard of care by many neurologists for valproate users.

RBC Folate (>400 ng/mL)

RBC folate reflects tissue stores over the past 120 days and is more reliable than serum folate. Critically important for women of childbearing age because valproate is the most teratogenic common medication. L-methylfolate supplementation (1-5 mg daily) is essential before and during any pregnancy exposure, though valproate should ideally be replaced with a less teratogenic anticonvulsant for women planning pregnancy.

25-OH Vitamin D (40-60 ng/mL)

Valproate induces CYP24A1 enzyme that accelerates vitamin D catabolism. The optimal range of 40-60 ng/mL is higher than the standard lab threshold of 30 ng/mL. Anticonvulsant users require the upper range to compensate for ongoing medication-induced catabolism. Supplement with 2,000-5,000 IU daily based on blood levels.

Valproic Acid Level (50-100 mcg/mL)

Therapeutic drug monitoring ensures adequate seizure control while minimizing dose-dependent nutrient depletion. Levels above 100 mcg/mL increase toxicity risk without proportional efficacy gains. Free valproate levels may be more informative than total levels because only 10% of valproate is protein-bound.

Ammonia (<35 µmol/L)

Elevated ammonia is the early warning signal for carnitine depletion severity. Hyperammonemia can cause encephalopathy, confusion, and vomiting that mimic seizure activity. Ammonia should be checked whenever a valproate user presents with unexplained confusion, lethargy, or behavioral changes — and always before attributing symptoms to seizure breakthrough.

LFTs (ALT/AST) (Normal range)

Liver function monitoring is mandatory for valproate users because carnitine depletion impairs hepatic fatty acid oxidation. Transaminase elevation above 3x the upper limit of normal warrants urgent evaluation. Children under 2 years old with polytherapy and metabolic disorders face the highest hepatotoxicity risk.

[05]

What vs Others

Name	Depletions	Potency	Notes
Valproic AcidThis drug	6 nutrients	High	Largest CTD footprint of any medication (34,261 genes), unique carnitine depletion, HDAC inhibitor
Phenytoin	6 nutrients	Moderate-High	Severe vitamin D and calcium depletion through CYP induction, gum overgrowth, no carnitine effect
Carbamazepine	6 nutrients	Moderate	Strong CYP inducer depleting D, calcium, folate, sodium (SIADH), B12, and biotin
Lamotrigine	3 nutrients	Low	Fewest depletions in the anticonvulsant class, no carnitine or bone effects

Valproic acid causes more nutrient depletions than any other anticonvulsant, with a unique carnitine depletion mechanism that no other common medication produces. Its 34,261 CTD gene interactions dwarf all other anticonvulsants, reflecting the HDAC inhibitor mechanism that affects gene expression across the entire genome. According to 43 randomized controlled trials across 75,066 patients, valproate remains a first-line treatment for generalized epilepsy and bipolar disorder, but its 6-nutrient depletion profile demands comprehensive monitoring that simpler medications like lamotrigine do not require.

[06]

Food Sources for Depleted Nutrients

Food	Amount per Serving
Beef steak	81 mg per 3 oz
Ground beef	87 mg per 3 oz
Pork chops	24 mg per 3 oz
Whole milk	8 mg per cup
Chicken breast	3 mg per 3 oz

Source: USDA Food Composition Database (658,209 food nutrient entries)

[07]

FAQ

[08]

References

[1]Comparative Toxicogenomics Database (CTD): 34,261 valproic acid gene interactions, 29,821 disease associations, 387 curated entries — largest medication footprint in the database (accessed April 2026)
[2]ChEMBL Database: Valproic acid classified as succinate semialdehyde dehydrogenase inhibitor, HDAC inhibitor (HDAC1/2/8), and GABA transaminase inhibitor, F=90%, T1/2=16h, PPB=10% (accessed April 2026)
[3]PharmGKB Database: Pharmacogenomic annotations linking UGT1A6, CYP2C9, and POLG variants to valproate metabolism, efficacy, and hepatotoxicity risk (accessed April 2026)
[4]PubMed: 3,337 indexed articles for valproic acid; 43 randomized controlled trials across 75,066 patients (accessed April 2026)
[5]FAERS Database: 30,120 total adverse event reports for valproic acid including hepatotoxicity, hyperammonemia, teratogenicity, and hair loss (accessed April 2026)

This information is generated from peer-reviewed molecular databases including the Comparative Toxicogenomics Database (CTD), ChEMBL, and indexed PubMed research. It is not medical advice. Always consult your healthcare provider before making changes to your medications or supplements. See our methodology →

Anticonvulsant Drug Class Overview

Compare nutrient depletions across all seizure medications

Phenytoin Nutrient Depletions

How phenytoin depletes vitamin D, calcium, and folate differently than valproic acid

Folate Deficiency Guide

Complete guide to folate testing, symptoms, and teratogenicity prevention

Check What YOUR Medications Deplete

Free. No signup. 10 seconds.

Check Now →

Contents

Check your medications

Check Free →